Hélène Sabatel
Direttore/Membro del Consiglio presso DeuterOncology SA
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Timothy Perera | M | - |
DeuterOncology SA
 DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | 4 anni |
| Staf van Reet | M | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | - |
| Serge Sagodira | M | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | - |
| Els Hubloux | F | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | - |
| Florence Wastelin | F | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Belgio | 5 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Hélène Sabatel
- Contatti personali
